-

Pyramid Biosciences to Present at the 2022 Jefferies London Healthcare Conference

WALTHAM, Mass.--(BUSINESS WIRE)--Pyramid Biosciences, Inc., a privately-held, clinical-stage biotechnology company focused on developing new and highly differentiated precision therapies for cancer and other serious diseases, announced today that Chief Executive Officer, Brian Lestini, M.D., Ph.D., will present at the 2022 Jefferies London Healthcare Conference on Thursday, November 17, 2022 at 2:40 PM GMT.

A live webcast of the presentation will be accessible on Pyramid’s website at Jefferies audiocast link or by visiting: https://wsw.com/webcast/jeff255/pyrb/1873179. A replay of the call will be archived for 90 days after the call.

For more information on the conference or to schedule a one-on-one meeting with the Pyramid Biosciences management, please contact your Jefferies representative.

About Pyramid Biosciences, Inc.
Founded in 2015, Pyramid Biosciences, Inc. is a Boston-based, clinical stage, biotechnology company dedicated to developing a portfolio of precision therapies targeting a wide range of molecularly defined diseases. Pyramid lead clinical program, PBI-200, is a novel, highly brain-penetrant, potential best-in-class TRK inhibitor for patients with NTRK-driven cancers. For more information, please visit www.pyramidbio.com.

Contacts

Pyramid Biosciences Media Inquiries:
McDougall Communications on behalf of Pyramid Biosciences
Elizabeth Harness, senior consultant: elizabeth@mcdougallpr.com

Pyramid Biosciences Investor Inquiries:
Biren Amin, Pyramid Biosciences, CFO, and Chief Strategy Officer
bamin@pyramidbio.com

Pyramid Biosciences, Inc.


Release Versions

Contacts

Pyramid Biosciences Media Inquiries:
McDougall Communications on behalf of Pyramid Biosciences
Elizabeth Harness, senior consultant: elizabeth@mcdougallpr.com

Pyramid Biosciences Investor Inquiries:
Biren Amin, Pyramid Biosciences, CFO, and Chief Strategy Officer
bamin@pyramidbio.com

Social Media Profiles
More News From Pyramid Biosciences, Inc.

Pyramid Biosciences to Present at the B. Riley Securities Third Annual Oncology Conference

WALTHAM, Mass.--(BUSINESS WIRE)--Pyramid Biosciences CEO Dr. Brian Lestini will present at the B. Riley Securities Oncology Conference on Thursday, January 19, 2023, at 2 pm ET....

Pyramid Biosciences Names Biren Amin as Chief Financial and Strategy Officer

WALTHAM, Mass.--(BUSINESS WIRE)--Pyramid Biosciences, Inc., a Boston-based, clinical-stage, biotechnology company focused on developing new and highly differentiated precision therapies for cancer, today announced the expansion of its senior leadership team. Biren Amin, M.S., M.B.A. has joined the company as its Chief Financial and Strategy Officer. Mr. Amin comes to Pyramid Biosciences from Immuneering Corporation (NASDAQ: IMRX), where he previously served as the company’s Chief Financial Offi...

Pyramid Biosciences Names Nushmia Khokhar, MD, as Chief Medical Officer

WALTHAM, Mass.--(BUSINESS WIRE)--Pyramid Biosciences, Inc., a Boston-based, clinical-stage biotechnology company focused on developing new and highly differentiated precision therapies for cancer and other serious diseases, today announced the expansion of its senior leadership team. Nushmia Khokhar, MD has joined the company as Chief Medical Officer, where she will oversee the advancement and expansion of the Company’s clinical pipeline. “Dr. Khokhar has a proven track record of successfully b...
Back to Newsroom